Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
À¶Ý®ÊÓƵ
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). Punekar, S., Hecht, J., Smith, C., Simeone, D. M., Dorigo, O., Boyd, L. R., Kirtane, K., Ward, J., Locke, F. L., Morelli, M., Block, M., Eskander, R., Langeberg, W. J., Liechty, K. B., Ong, G. S., Go, W. Y., Maloney, D. G., Maus, M., Welch, J., Molina, J. R. LIPPINCOTT WILLIAMS & WILKINS. 2024View details for